Trial · NCT07252401
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction
NCT07252401, Not applicable, Not yet recruiting, General Hospital of Shenyang Military Region
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction. Trials, record NCT07252401. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07252401
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction
- NCT number
- NCT07252401
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 64 participants, estimated
- Lead sponsor
- General Hospital of Shenyang Military Region
- Conditions
- Liver Cirrhosis
- Interventions
- 2-4 mg of terlipressin, 3 mg of somatostatin
- First posted
- 2025-11-26
- Last updated
- 2026-08-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Renal function recovery | 6 weeks | The renal function recovery is defined as SCr level ≤ 1.5 mg/dl (133 μmol/L) in two consecutive measurements with an interval of at least 2 hours between them. |
| Secondary | Incidence of AKI within 7 days | 7 days | Clinical symptoms related to AKI occur and SCr levels increase after the treatment. The diagnosis of AKI should meet any one of the following conditions: 1) an increase in SCr level of ≥ 0.3 mg/dl (26.5 μmol/L) within 48 hours; 2) an increase in SCr level to ≥ 1.5 times the baseline value within 7 days; 3) a urine output of \< 0.5 ml/kg per hour for a continuous 6 hours. |
| Secondary | 5-day failure to control bleeding | 5 days | The 5-day failure to control bleeding is defined as failure to achieve effective control of AVB or occurrence of rebleeding within 5 days after treatment. |
| Secondary | Kidney replacement therapy rate | 6 weeks | Participants undergo dialysis or continuous kidney replacement therapy due to failure to recover renal function after treatment. |
| Secondary | Transjugular intrahepatic portosystemic shunt (TIPS) treatment rate | 6 weeks | Participants undergo transjugular intrahepatic portosystemic shunt (TIPS) treatment. |
| Secondary | Liver and kidney transplantation treatment rate | 6 weeks | Participants undergo liver and kidney transplantation treatment. |
| Secondary | 6-week mortality rate | 6 weeks | The 6-week mortality rate is defined as the all-cause mortality rate over 6 weeks. |
| Secondary | 6-week rebleeding rate | 6 weeks | The 6-week rebleeding rate is defined as the rebleeding rate within 6 weeks after successful AVB hemostasis. |
| Secondary | Adverse events | 6 weeks | Adverse events will be monitored, including nausea, abdominal pain, diarrhea, arrhythmia, dyspnea, and hyponatremia that may be caused by terlipressin, as well as nausea, abdominal pain, diarrhea, hypoglycemia, and allergies that may be caused by somatostatin. The incidence of adverse events is defined as rate of adverse reactions secondary to terlipressin or somatostatin, endoscopic therapy or interventional procedures during study periods. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07252401
GET https://conductscience.org/api/trials/v1/NCT07252401/registered